Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
National Capital Clinical Research Consortium
mi
from
Bethesda, MD
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
National Capital Clinical Research Consortium
mi
from
Bethesda, MD
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Jackson Oncology Associates
mi
from
Jackson, MS
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Jackson Oncology Associates
mi
from
Jackson, MS
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
St. Louis Cancer Care
mi
from
Chesterfield, MO
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
St. Louis Cancer Care
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Research Medical Center
mi
from
Kansas City, MO
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Nebraska Methodist Cancer Center
mi
from
Omaha, NE
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Nebraska Methodist Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated:  3/10/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Status: Enrolling
Updated: 3/10/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Decatur Memorial Hospital
mi
from
Decatur, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Loyola University Medical Center
mi
from
Maywood, IL
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  3/10/2016
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 3/10/2016
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Ironwood Cancer and Research Centers SC
mi
from
Chandler, AZ
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Ironwood Cancer and Research Centers SC
mi
from
Chandler, AZ
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Arizona Oncology Associates Tucson (Rudasill & La Cholla)
mi
from
Phoenix, AZ
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Arizona Oncology Associates Tucson (Rudasill & La Cholla)
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr.
mi
from
Los Angeles, CA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
University of California at San Diego, Moores Cancer Ctr SC
mi
from
San Diego, CA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
University of California at San Diego, Moores Cancer Ctr SC
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
University of Colorado Univ CO
mi
from
Aurora, CO
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
University of Colorado Univ CO
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
mi
from
Greenwood Village, CO
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt
mi
from
Tampa, FL
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Emory University School of Medicine/Winship Cancer Institute Emory 2
mi
from
Atlanta, GA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Emory University School of Medicine/Winship Cancer Institute Emory 2
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
University of Chicago Medical Center Unvi Chi
mi
from
Chicago, IL
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
University of Chicago Medical Center Unvi Chi
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Rush University Medical Center SC
mi
from
Chicago, IL
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Rush University Medical Center SC
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
University of Kansas Cancer Center Univ of KS
mi
from
Kansas City, KA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
University of Kansas Cancer Center Univ of KS
mi
from
Kansas City, KA
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Massachusetts General Hospital Mass General
mi
from
Boston, MA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Massachusetts General Hospital Mass General
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2)
mi
from
Morristown, NJ
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2)
mi
from
Morristown, NJ
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Overlook Hospital - Carol G Simon Cancer Center Carol G Simon
mi
from
Summit, NJ
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Overlook Hospital - Carol G Simon Cancer Center Carol G Simon
mi
from
Summit, NJ
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Roswell Park Cancer Institute Rosewell
mi
from
Buffalo, NY
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Roswell Park Cancer Institute Rosewell
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Duke University Medical Center Duke 2
mi
from
Durham, NC
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Duke University Medical Center Duke 2
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
MetroHealth Medical Center Dept.ofMetroHealthMedCtr.(2)
mi
from
Cleveland, OH
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
MetroHealth Medical Center Dept.ofMetroHealthMedCtr.(2)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
University of Oklahoma Health Sciences Center Dept. of Oklahoma Univ. HSC
mi
from
Oklahoma City, OK
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
University of Oklahoma Health Sciences Center Dept. of Oklahoma Univ. HSC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Northwest Cancer Specialists Compass Oncology -BKM
mi
from
Portland, OR
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Northwest Cancer Specialists Compass Oncology -BKM
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
University of Pittsburgh Medical Center SC-2
mi
from
Pittsburgh, PA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
University of Pittsburgh Medical Center SC-2
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Medical University of South Carolina
mi
from
Charleston, SC
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Baylor Health Care System / Sammons Cancer Center Baylor Texas Oncology
mi
from
Dallas, TX
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Baylor Health Care System / Sammons Cancer Center Baylor Texas Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office
mi
from
Dallas, TX
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Virginia Oncology Associates VOA - Lake Wright (2)
mi
from
*see Various Departments*, VA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Virginia Oncology Associates VOA - Lake Wright (2)
mi
from
*see Various Departments*, VA
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
University of Wisconsin Univ WIsc 2
mi
from
Madison, WI
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
University of Wisconsin Univ WIsc 2
mi
from
Madison, WI
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Mayo Clinic - Arizona Mayo Scottsdale AZ
mi
from
Scottsdale, AZ
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Mayo Clinic - Arizona Mayo Scottsdale AZ
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated:  3/10/2016
Fallon Clinic at Worcester Medical Center Fallon Clinic Worcester Med
mi
from
Worcester, MA
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
Status: Enrolling
Updated: 3/10/2016
Fallon Clinic at Worcester Medical Center Fallon Clinic Worcester Med
mi
from
Worcester, MA
Click here to add this to my saved trials